APM
RPRX icon

Avidity Partners Management’s Royalty Pharma RPRX Stock Holding History

Avidity Partners Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,000
Closed -$2.71M – 81
2025
Q1 		$2.71M Buy
+87,000
New +$2.76M 0.52% 49
2020
Q3 		– Sell
-200,000
Closed -$9.71M – 85
2020
Q2 		$9.71M Buy
+200,000
New +$9.9M 0.62% 44

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Avidity Partners Management's RPRX Position: Q2 2025 in Review

Avidity Partners Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 87,000 shares — an estimated $2.71M sold.

Avidity Partners Management first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $9.71M in Q2 2020. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Avidity Partners Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 87,000 Royalty Pharma shares in Q2 2025, an estimated $2.71M.
  • Avidity Partners Management first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
  • Avidity Partners Management's Royalty Pharma position peaked at $9.71M in Q2 2020.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.